Wu Zhengyu, Zhang Fang, Liu Chengzhu, Shen Shuhong, Chu Jinhua, Yang Linhai, Xie Zhiwei, Liu Yu, Liu Kangkang, Wang Ningling
Pediatrics, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Oncol. 2022 Aug 16;12:900054. doi: 10.3389/fonc.2022.900054. eCollection 2022.
Previous studies have shown that, the clinical features and prognosis of ZNF384-rearranged pediatric acute lymphoblastic leukemia (ALL) depend on its translocation partners. We report two cases of TCF4-ZNF384 fusion, one 6-year-old girl and one 10-year-old boy, both diagnosed by whole-transcriptome sequencing, and TCF4 is the newest fusion partner of ZNF384. As illustrated in this first report of TCF4-ZNF384 fusion in ALL patients, the identification of patients with ZNF384 rearrangement in ALL patients is critical to elucidate outcomes associated with a specific rearrangement and to develop appropriate treatment strategies. In addition, the development of other methods to detect ZNF384 specific translocation partners and leukemia specific targeting agents is of great significance to further improve the prognosis of ALL with ZNF384-rearrangement.
既往研究表明，ZNF384重排的儿童急性淋巴细胞白血病（ALL）的临床特征和预后取决于其易位伙伴。我们报告了2例TCF4-ZNF384融合病例，1例6岁女孩和1例10岁男孩，均通过全转录组测序确诊，且TCF4是ZNF384最新的融合伙伴。在这篇ALL患者中TCF4-ZNF384融合的首例报告中表明，识别ALL患者中的ZNF384重排对于阐明与特定重排相关的结局以及制定合适的治疗策略至关重要。此外，开发其他检测ZNF384特异性易位伙伴的方法以及白血病特异性靶向药物对于进一步改善ZNF384重排ALL的预后具有重要意义。
